Acorda Therapeutics (ACOR) Receives Daily Media Sentiment Rating of 0.11
News stories about Acorda Therapeutics (NASDAQ:ACOR) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.3756409489914 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- [$$] The Payoff in ADP (finance.yahoo.com)
- Acorda Therapeutics, Inc. (ACOR) 5.57% off from 200- SMA: Acorda Therapeutics, Inc. (ACOR) – Voice Of Analysts (analystsbuzz.com)
- $0.40 EPS Expected for Acorda Therapeutics, Inc. (NASDAQ:ACOR) This Quarter (americanbankingnews.com)
- Choosing Between Lexicon Pharmaceuticals, Inc. (LXRX) and Acorda Therapeutics, Inc. (ACOR) – StockNewsGazette (stocknewsgazette.com)
- IHS Markit Score Update: Drop in demand for ETFs holding Acorda Therapeutics Inc is a negative sign for its shares (finance.yahoo.com)
A number of brokerages recently issued reports on ACOR. BidaskClub downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a research report on Friday, July 28th. Zacks Investment Research downgraded Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Jefferies Group LLC began coverage on Acorda Therapeutics in a research report on Monday, July 10th. They set a “hold” rating and a $22.00 price objective for the company. Finally, J P Morgan Chase & Co set a $24.00 price objective on Acorda Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, June 6th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $25.26.
Acorda Therapeutics (ACOR) opened at 21.35 on Friday. The stock’s market capitalization is $995.76 million. The company’s 50-day moving average price is $20.82 and its 200-day moving average price is $20.34. Acorda Therapeutics has a one year low of $13.60 and a one year high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.16. The company had revenue of $139.40 million during the quarter, compared to analyst estimates of $139.81 million. Acorda Therapeutics had a negative return on equity of 6.37% and a negative net margin of 8.02%. The firm’s revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 earnings per share. Equities research analysts predict that Acorda Therapeutics will post $1.71 EPS for the current year.
In other news, insider Ron Cohen purchased 20,000 shares of the company’s stock in a transaction on Friday, June 16th. The stock was bought at an average cost of $16.95 per share, for a total transaction of $339,000.00. Following the completion of the purchase, the insider now directly owns 511,648 shares of the company’s stock, valued at approximately $8,672,433.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew A. Hindman sold 7,704 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $15.75, for a total value of $121,338.00. Following the sale, the insider now owns 46,123 shares of the company’s stock, valued at $726,437.25. The disclosure for this sale can be found here. Insiders have sold 27,704 shares of company stock valued at $553,638 over the last 90 days. 7.90% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/13/acorda-therapeutics-acor-receives-daily-media-sentiment-rating-of-0-11.html.
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Stock Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related stocks with our FREE daily email newsletter.